Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers of Diabetic Retinopathy

  • Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic retinopathy (DR), a leading cause of acquired vision loss, is a microvascular complication of diabetes. While traditional risk factors for diabetic retinopathy including longer duration of diabetes, poor blood glucose control, and dyslipidemia are helpful in stratifying patient’s risk for developing retinopathy, many patients without these traditional risk factors develop DR; furthermore, there are persons with long diabetes duration who do not develop DR. Thus, identifying biomarkers to predict DR or to determine therapeutic response is important. A biomarker can be defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Incorporation of biomarkers into risk stratification of persons with diabetes would likely aid in early diagnosis and guide treatment methods for those with DR or with worsening DR. Systemic biomarkers of DR include serum measures including genomic, proteomic, and metabolomics biomarkers. Ocular biomarkers including tears and vitreous and retinal vascular structural changes have also been studied extensively to prognosticate the risk of DR development. The current studies on biomarkers are limited by the need for larger sample sizes, cross-validation in different populations and ethnic groups, and time-efficient and cost-effective analytical techniques. Future research is important to explore novel DR biomarkers that are non-invasive, rapid, economical, and accurate to help reduce the incidence and progression of DR in people with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Ting DSW, Cheung CM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–77. This study provides the updated DR epidemiology (incidence and progression) and risk factors; various screening practices using different imaging modalities.

    Article  PubMed  Google Scholar 

  2. Diabetes Atlas, 3rd Edition. Brussels: International Diabetes Federation. [database on the Internet]2014. Available from: http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance. Accessed 3 Feb 2011.

  3. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83. doi:10.1080/09286580701396720.

    Article  PubMed  Google Scholar 

  4. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. doi:10.1016/S0140-6736(09)62124-3.

    Article  PubMed  Google Scholar 

  5. International Diabetes Federation. Diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2015.

    Google Scholar 

  6. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2(7):566–80. doi:10.1038/nrd1130.

    Article  CAS  PubMed  Google Scholar 

  7. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest. 2012;42(2):216–28. doi:10.1111/j.1365-2362.2011.02562.x.

    Article  PubMed  Google Scholar 

  8. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647–61.

    Article  Google Scholar 

  9. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381–9. doi:10.1056/NEJM200002103420603.

    Article  PubMed Central  Google Scholar 

  10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

    Article  Google Scholar 

  11. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902–16. doi:10.1001/jama.298.8.902.

    Article  CAS  PubMed  Google Scholar 

  12. Song J, Chen S, Liu X, Duan H, Kong J, Li Z. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0144406. doi:10.1371/journal.pone.0144406.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol. 2014;9:167. doi:10.1186/s13000-014-0167-y.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Roy MS, Janal MN, Crosby J, Donnelly R. Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci. 2013;54(8):5471–80. doi:10.1167/iovs.13-12212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sharma S, Purohit S, Sharma A, Hopkins D, Steed L, Bode B, et al. Elevated serum levels of soluble TNF receptors and adhesion molecules are associated with diabetic retinopathy in patients with type-1 diabetes. Mediat Inflamm. 2015;2015:279393. doi:10.1155/2015/279393.

    Article  CAS  Google Scholar 

  16. van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48(7):1300–6. doi:10.1007/s00125-005-1799-y.

    Article  CAS  PubMed  Google Scholar 

  17. Simo R, Masmiquel L, Garcia-Pascual L, Burgos R, Mateo C, Segura RM, et al. Serum concentrations of laminin-P1 in diabetes mellitus: usefulness as an index of diabetic microangiopathy. Diabetes Res Clin Pract. 1996;32(1–2):45–53.

    Article  CAS  PubMed  Google Scholar 

  18. Masmiquel L, Segura RM, Mateo C, Calatayud M, Marti R, Mesa J, et al. Serum laminin as a marker of diabetic retinopathy development: a 4-year follow-up study. Am J Ophthalmol. 2000;129(3):347–52.

    Article  CAS  PubMed  Google Scholar 

  19. Zhou W, Hu W. Serum and vitreous pentraxin 3 concentrations in patients with diabetic retinopathy. Genet Test Mol Biomarkers. 2016;20(3):149–53. doi:10.1089/gtmb.2015.0238.

    Article  CAS  PubMed  Google Scholar 

  20. Dong N, Shi H, Xu B, Cai Y. Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in Type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2015;56(8):4177–85. doi:10.1167/iovs.15-16470.

    Article  CAS  PubMed  Google Scholar 

  21. Sinha S, Saxena S, Das S, Prasad S, Bhasker SK, Mahdi AA, et al. Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy. J Diabetes Complicat. 2016;30(4):700–4. doi:10.1016/j.jdiacomp.2016.01.010.

    Article  PubMed  Google Scholar 

  22. Huang Q, Shang G, Deng H, Liu J, Mei Y, Xu Y. High mannose-binding lectin serum levels are associated with diabetic retinopathy in chinese patients with Type 2 diabetes. PLoS One. 2015;10(7):e0130665. doi:10.1371/journal.pone.0130665.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Li ZZ, Lu XZ, Liu JB, Chen L. Serum retinol-binding protein 4 levels in patients with diabetic retinopathy. J Int Med Res. 2010;38(1):95–9.

    Article  PubMed  Google Scholar 

  24. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007;92(7):2712–9. doi:10.1210/jc.2006-1249.

    Article  CAS  PubMed  Google Scholar 

  25. Domingueti CP, Fuzatto JA, Foscolo RB, Reis JS, Dusse LM, Carvalho MD, et al. Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d-Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus. Clin Chim Acta. 2016;459:1–4. doi:10.1016/j.cca.2016.05.011.

    Article  CAS  PubMed  Google Scholar 

  26. Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, McCarren M, et al. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2014;37(2):501–6. doi:10.2337/dc13-1193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004;47(8):1376–9. doi:10.1007/s00125-004-1455-y.

    Article  CAS  PubMed  Google Scholar 

  28. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab. 2003;29(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  29. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G, et al. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011;60(2):582–9. doi:10.2337/db10-0915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lin Y, Xiao YC, Zhu H, Xu QY, Qi L, Wang YB, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res. 2014;2014:929756. doi:10.1155/2014/929756.

    PubMed  PubMed Central  Google Scholar 

  31. Fan X, Wu Q, Li Y, Hao Y, Ning N, Kang Z, et al. Association between adiponectin concentrations and diabetic retinopathy in patients with type 2 diabetes: a meta analysis. Chin Med J (Engl). 2014;127(4):765–71.

    Google Scholar 

  32. Wong CW, Teo BW, Lamoureux E, Ikram MK, Wang JJ, Tai ES, et al. Serum cystatin C, markers of chronic kidney disease, and retinopathy in persons with diabetes. J Diabetes Res. 2015;2015:404280. doi:10.1155/2015/404280.

    Article  PubMed  PubMed Central  Google Scholar 

  33. He R, Shen J, Zhao J, Zeng H, Li L, Zhao J, et al. High cystatin C levels predict severe retinopathy in type 2 diabetes patients. Eur J Epidemiol. 2013;28(9):775–8. doi:10.1007/s10654-013-9839-2.

    Article  PubMed  Google Scholar 

  34. Gopalakrishnan V, Purushothaman P, Bhaskar A. Proteomic analysis of plasma proteins in diabetic retinopathy patients by two dimensional electrophoresis and MALDI-Tof-MS. J Diabetes Complicat. 2015;29(7):928–36. doi:10.1016/j.jdiacomp.2015.05.021.

    Article  PubMed  Google Scholar 

  35. Lu CH, Lin ST, Chou HC, Lee YR, Chan HL. Proteomic analysis of retinopathy-related plasma biomarkers in diabetic patients. Arch Biochem Biophys. 2013;529(2):146–56. doi:10.1016/j.abb.2012.11.004.

    Article  CAS  PubMed  Google Scholar 

  36. Liu YP, Hu SW, Wu ZF, Mei LX, Lang P, Lu XH. Proteomic analysis of human serum from diabetic retinopathy. Int J Ophthalmol. 2011;4(6):616–22. doi:10.3980/j.issn.2222-3959.2011.06.08.

    PubMed  PubMed Central  Google Scholar 

  37. Chen L, Cheng CY, Choi H, Ikram MK, Sabanayagam C, Tan GS, et al. Plasma metabonomic profiling of diabetic retinopathy. Diabetes. 2016;65(4):1099–108. doi:10.2337/db15-0661.

    Article  CAS  PubMed  Google Scholar 

  38. Xia JF, Wang ZH, Liang QL, Wang YM, Li P, Luo GA. Correlations of six related pyrimidine metabolites and diabetic retinopathy in Chinese type 2 diabetic patients. Clin Chim Acta. 2011;412(11–12):940–5. doi:10.1016/j.cca.2011.01.025.

    Article  CAS  PubMed  Google Scholar 

  39. Garcia de la Torre N, Fernandez-Durango R, Gomez R, Fuentes M, Roldan-Pallares M, Donate J, et al. Expression of angiogenic MicroRNAs in endothelial progenitor cells from type 1 diabetic patients with and without diabetic retinopathy. Invest Ophthalmol Vis Sci. 2015;56(6):4090–8. doi:10.1167/iovs.15-16498.

    Article  CAS  PubMed  Google Scholar 

  40. Qing S, Yuan S, Yun C, Hui H, Mao P, Wen F, et al. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol Biochem. 2014;34(5):1733–40. doi:10.1159/000366374.

    Article  CAS  PubMed  Google Scholar 

  41. Zampetaki A, Willeit P, Burr S, Yin X, Langley SR, Kiechl S, et al. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes. 2016;65(1):216–27. doi:10.2337/db15-0389.

    CAS  PubMed  Google Scholar 

  42. Zeng J, Xiong Y, Li G, Liu M, He T, Tang Y, et al. MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. Exp Clin Endocrinol Diabetes. 2013;121(7):425–30. doi:10.1055/s-0033-1345169.

    Article  CAS  PubMed  Google Scholar 

  43. Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay WT, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52(10):7593–602. doi:10.1167/iovs.11-7510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zitman-Gal T, Green J, Pasmanik-Chor M, Golan E, Bernheim J, Benchetrit S. Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment. Cardiovasc Diabetol. 2014;13:8. doi:10.1186/1475-2840-13-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Looker HC, Nelson RG, Chew E, Klein R, Klein BE, Knowler WC, et al. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes. 2007;56(4):1160–6. doi:10.2337/db06-1299.

    Article  CAS  PubMed  Google Scholar 

  46. Hietala K, Forsblom C, Summanen P, Groop PH, FinnDiane Study G. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57(8):2176–80. doi:10.2337/db07-1495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839–45. doi:10.1167/iovs.07-1633.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Salman AG, Mansour DE, Swelem AH, Al-Zawahary WM, Radwan AA. Pentosidine - a new biochemical marker in diabetic retinopathy. Ophthalmic Res. 2009;42(2):96–8. doi:10.1159/000225661.

    Article  CAS  PubMed  Google Scholar 

  49. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One. 2008;3(10):e3583. doi:10.1371/journal.pone.0003583.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Musunuru K, Lettre G, Young T, Farlow DN, Pirruccello JP, Ejebe KG, et al. Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet. 2010;3(3):267–75. doi:10.1161/CIRCGENETICS.109.882696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010. doi:10.1155/2010/861291.

    PubMed  PubMed Central  Google Scholar 

  52. Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642–8. doi:10.1016/j.ophtha.2010.07.020.

    Article  PubMed  Google Scholar 

  53. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472–81. doi:10.1093/hmg/ddr121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Sheu WH, Kuo JZ, Lee IT, Hung YJ, Lee WJ, Tsai HY, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22(15):3165–73. doi:10.1093/hmg/ddt161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS One. 2014;9(11):e111715. doi:10.1371/journal.pone.0111715.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia. 2015;58(10):2288–97. doi:10.1007/s00125-015-3697-2.

    Article  CAS  PubMed  Google Scholar 

  57. Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab (Seoul). 2015;30(2):147–58. doi:10.3803/EnM.2015.30.2.147.

    Article  Google Scholar 

  58. Hosseini SM, Boright AP, Sun L, Canty AJ, Bull SB, Klein BE, et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet. 2015;134(2):247–57. doi:10.1007/s00439-014-1517-2.

    Article  CAS  PubMed  Google Scholar 

  59. Zeng Y, Dai F, Yang K, Tang Y, Xu M, Zhou Y. Association between a vascular endothelial growth factor gene polymorphism (rs2146323) and diabetic retinopathy: a meta-analysis. BMC Ophthalmol. 2015;15:163. doi:10.1186/s12886-015-0155-3.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Lu Y, Ge Y, Shi Y, Yin J, Huang Z. Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis. BMC Ophthalmol. 2013;13:56. doi:10.1186/1471-2415-13-56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Qiu M, Xiong W, Liao H, Li F. VEGF -634G>C polymorphism and diabetic retinopathy risk: a meta-analysis. Gene. 2013;518(2):310–5. doi:10.1016/j.gene.2013.01.018.

    Article  CAS  PubMed  Google Scholar 

  62. Han L, Zhang L, Xing W, Zhuo R, Lin X, Hao Y, et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case–control studies. J Diabetes Res. 2014;2014:805801. doi:10.1155/2014/805801.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis. PLoS One. 2013;8(12):e84069. doi:10.1371/journal.pone.0084069.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Ding Y, Hu Z, Yuan S, Xie P, Liu Q. Association between transcription factor 7-like 2 rs7903146 polymorphism and diabetic retinopathy in type 2 diabetes mellitus: a meta-analysis. Diab Vasc Dis Res. 2015;12(6):436–44. doi:10.1177/1479164115598274.

    Article  CAS  PubMed  Google Scholar 

  65. Fan WY, Liu NP. Meta-analysis of association between K469E polymorphism of the ICAM-1 gene and retinopathy in type 2 diabetes. Int J Ophthalmol. 2015;8(3):603–7. doi:10.3980/j.issn.2222-3959.2015.03.30.

    PubMed  PubMed Central  Google Scholar 

  66. Zhang J, Liu H, Yan H, Huang G, Wang B. Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis. Gene. 2013;518(2):405–11. doi:10.1016/j.gene.2012.12.086.

    Article  CAS  PubMed  Google Scholar 

  67. Zhou M, Zhang P, Xu X, Sun X. The relationship between aldose reductase C106T polymorphism and diabetic retinopathy: an updated meta-analysis. Invest Ophthalmol Vis Sci. 2015;56(4):2279–89. doi:10.1167/iovs.14-16279.

    Article  CAS  PubMed  Google Scholar 

  68. Liu L, Jiao J, Wang Y, Wu J, Huang D, Teng W, et al. TGF-beta1 gene polymorphism in association with diabetic retinopathy susceptibility: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94160. doi:10.1371/journal.pone.0094160.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Wang J, Yang MM, Rong SS, Ng TK, Li YB, Liu XM. Association of paraoxonase gene polymorphisms with diabetic nephropathy and retinopathy. Mol Med Rep. 2013;8(6):1845–51. doi:10.3892/mmr.2013.1710.

    CAS  PubMed  Google Scholar 

  70. Zhang T, Pang C, Li N, Zhou E, Zhao K. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis. BMC Med. 2013;11:1. doi:10.1186/1741-7015-11-1.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Ma J, Li Y, Zhou F, Xu X, Guo G, Qu Y. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene and diabetic retinopathy in Caucasians and Asians. Mol Vis. 2012;18:2352–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Zhao S, Li T, Zheng B, Zheng Z. Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms in association with diabetic retinopathy susceptibility: a meta-analysis. Ophthalmic Genet. 2012;33(4):200–7. doi:10.3109/13816810.2012.675398.

    Article  CAS  PubMed  Google Scholar 

  73. Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia. 2011;54(4):803–11. doi:10.1007/s00125-010-2004-5.

    Article  CAS  PubMed  Google Scholar 

  74. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011;55(3):256–63. doi:10.1007/s10384-011-0004-8.

    Article  CAS  PubMed  Google Scholar 

  75. Simo R, Vidal MT, Garcia-Arumi J, Carrasco E, Garcia-Ramirez M, Segura RM, et al. Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case–control study. Diabetes Res Clin Pract. 2006;71(1):36–44. doi:10.1016/j.diabres.2005.05.017.

    Article  CAS  PubMed  Google Scholar 

  76. Katsura Y, Okano T, Noritake M, Kosano H, Nishigori H, Kado S, et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care. 1998;21(10):1759–63.

    Article  CAS  PubMed  Google Scholar 

  77. Simo R, Hernandez C, Segura RM, Garcia-Arumi J, Sararols L, Burgos R, et al. Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case–control study. Clin Sci (London, England : 1979). 2003;104(3):223–30. doi:10.1042/cs20020278.

    Article  CAS  Google Scholar 

  78. Simo R, Lecube A, Segura RM, Garcia Arumi J, Hernandez C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134(3):376–82.

  79. Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000;23(1):80–3.

  80. You JJ, Yang CM, Chen MS, Yang CH. Elevation of angiogenic factor Cysteine-rich 61 levels in vitreous of patients with proliferative diabetic retinopathy. Retina (Philadelphia, Pa). 2012;32(1):103–11. doi:10.1097/IAE.0b013e318219e4ad.

    Article  CAS  Google Scholar 

  81. Zhang X, Yu W, Dong F. Cysteine-rich 61 (CYR61) is up-regulated in proliferative diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2012;250(5):661–8. doi:10.1007/s00417-011-1882-7.

    Article  CAS  Google Scholar 

  82. You JJ, Yang CH, Chen MS, Yang CM. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(7):3447–55. doi:10.1167/iovs.08-2603.

    Article  PubMed  Google Scholar 

  83. Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, et al. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res. 2009;34(2):152–61. doi:10.1080/02713680802585920.

    Article  CAS  PubMed  Google Scholar 

  84. Praidou A, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmol. 2011;89(3):248–54. doi:10.1111/j.1755-3768.2009.01661.x.

    Article  CAS  PubMed  Google Scholar 

  85. Li JK, Wei F, Jin XH, Dai YM, Cui HS, Li YM. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab. Int J Ophthalmol. 2015;8(6):1202–6. doi:10.3980/j.issn.2222-3959.2015.06.22.

    PubMed  PubMed Central  Google Scholar 

  86. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71–98.

    Article  CAS  PubMed  Google Scholar 

  87. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res. 2006;82(5):798–806.

  88. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139(3):476–81. doi:10.1016/j.ajo.2004.10.004.

    Article  CAS  PubMed  Google Scholar 

  89. Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J, et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol. 2013;91(6):531–9. doi:10.1111/j.1755-3768.2012.02473.x.

    Article  CAS  PubMed  Google Scholar 

  90. Xu Y, Cheng Q, Yang B, Yu S, Xu F, Lu L, et al. Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Invest Ophthalmol Vis Sci. 2015;56(11):6565–72. doi:10.1167/iovs.15-16854.

    Article  CAS  PubMed  Google Scholar 

  91. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res. 2006;82(5):798–806. doi:10.1016/j.exer.2005.10.002.

    Article  CAS  PubMed  Google Scholar 

  92. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes. 2001;50(12):2641–5.

    Article  CAS  PubMed  Google Scholar 

  93. Ogata N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol. 2001;132(3):378–82.

    Article  CAS  PubMed  Google Scholar 

  94. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002;134(3):348–53.

    Article  CAS  PubMed  Google Scholar 

  95. Boehm BO, Lang G, Feldmann B, Kurkhaus A, Rosinger S, Volpert O, et al. Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. a pilot study. Horm Metab Res = Hormon Stoffwechselforschung = Horm Metab. 2003;35(6):382–6. doi:10.1055/s-2003-41362.

    Article  CAS  Google Scholar 

  96. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol Diabetes. 1999;107(1):21–8. doi:10.1055/s-0029-1212068.

    Article  CAS  PubMed  Google Scholar 

  97. Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137–48. doi:10.1016/j.phrs.2015.05.013.

    Article  CAS  PubMed  Google Scholar 

  98. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev. 2010;6(5):304–12.

    Article  CAS  PubMed  Google Scholar 

  99. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189(2):824–31.

    Article  CAS  PubMed  Google Scholar 

  100. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch Int J Pathol. 1995;426(5):479–86.

    Article  CAS  Google Scholar 

  101. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463–7.

    Article  CAS  PubMed  Google Scholar 

  102. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47(12):1953–9.

    Article  CAS  PubMed  Google Scholar 

  103. Campochiaro PA, Hackett SF, Vinores SA, Freund J, Csaky C, LaRochelle W, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci. 1994;107(Pt 9):2459–69.

    CAS  PubMed  Google Scholar 

  104. Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, Larochelle W, et al. Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells. Exp Eye Res. 1995;60(6):607–19.

    Article  CAS  PubMed  Google Scholar 

  105. Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci. 2000;41(5):1210–6.

    CAS  PubMed  Google Scholar 

  106. Yokota T, Ma RC, Park JY, Isshiki K, Sotiropoulos KB, Rauniyar RK, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003;52(3):838–45.

    Article  CAS  PubMed  Google Scholar 

  107. Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40(9):1107–9. doi:10.1007/s001250050794.

    Article  CAS  PubMed  Google Scholar 

  108. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75(3):1028–36. doi:10.1172/jci111764.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia. 1993;36(4):282–91.

    Article  CAS  PubMed  Google Scholar 

  110. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993;48(1–2):267–78.

    Article  CAS  PubMed  Google Scholar 

  111. Danis RP, Bingaman DP. Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology. 1997;104(10):1661–9.

    Article  CAS  PubMed  Google Scholar 

  112. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991;53(3):411–4.

    Article  CAS  PubMed  Google Scholar 

  113. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (New York, NY). 1999;285(5425):245–8.

    Article  CAS  Google Scholar 

  114. Holtkamp GM, De Vos AF, Peek R, Kijlsta A. Analysis of the secretion pattern of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor-beta 2 (TGF-beta2) by human retinal pigment epithelial cells. Clin Exp Immunol. 1999;118(1):35–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Eichler W, Yafai Y, Kuhrt H, Grater R, Hoffmann S, Wiedemann P, et al. Hypoxia: modulation of endothelial cell proliferation by soluble factors released by retinal cells. Neuroreport. 2001;12(18):4103–8.

    Article  CAS  PubMed  Google Scholar 

  116. Katsura MK, Mishima HK, Minamoto A, Ishibashi F, Yamashita H. Growth regulation of bovine retinal pericytes by transforming growth factor-beta2 and plasmin. Curr Eye Res. 2000;20(3):166–72.

    Article  CAS  PubMed  Google Scholar 

  117. Kawai S, Nakajima T, Hokari S, Komoda T, Kawai K. Apolipoprotein A-I concentration in tears in diabetic retinopathy. Ann Clin Biochem. 2002;39(Pt 1):56–61.

    Article  CAS  PubMed  Google Scholar 

  118. Zhao Z, Liu J, Shi B, He S, Yao X, Willcox MD. Advanced glycation end product (AGE) modified proteins in tears of diabetic patients. Mol Vis. 2010;16:1576–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  119. Moschos MM, Rouvas AA, Papadimitriou S, Kotsolis A, Sitaras N, Apostolopoulos M. Quantitative determination of glycosaminoglycans in tears of diabetic patients. Clin Ophthalmol. 2008;2(3):581–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Yu L, Chen X, Qin G, Xie H, Lv P. Tear film function in type 2 diabetic patients with retinopathy. Ophthalmologica. 2008;222(4):284–91. doi:10.1159/000140256.

    Article  PubMed  Google Scholar 

  121. Herber S, Grus FH, Sabuncuo P, Augustin AJ. Two-dimensional analysis of tear protein patterns of diabetic patients. Electrophoresis. 2001;22(9):1838–44. doi:10.1002/1522-2683(200105)22:9<1838::AID-ELPS1838>3.0.CO;2-7.

    Article  CAS  PubMed  Google Scholar 

  122. Zhou L, Beuerman RW, Foo Y, Liu S, Ang LP, Tan DT. Characterisation of human tear proteins using high-resolution mass spectrometry. Ann Acad Med Singapore. 2006;35(6):400–7.

    PubMed  Google Scholar 

  123. Li N, Wang N, Zheng J, Liu XM, Lever OW, Erickson PM, et al. Characterization of human tear proteome using multiple proteomic analysis techniques. J Proteome Res. 2005;4(6):2052–61. doi:10.1021/pr0501970.

    Article  CAS  PubMed  Google Scholar 

  124. Sack RA, Conradi L, Krumholz D, Beaton A, Sathe S, Morris C. Membrane array characterization of 80 chemokines, cytokines, and growth factors in open- and closed-eye tears: angiogenin and other defense system constituents. Invest Ophthalmol Vis Sci. 2005;46(4):1228–38. doi:10.1167/iovs.04-0760.

    Article  PubMed  Google Scholar 

  125. Lei Z, Beuerman RW, Chew AP, Koh SK, Cafaro TA, Urrets-Zavalia EA, et al. Quantitative analysis of N-linked glycoproteins in tear fluid of climatic droplet keratopathy by glycopeptide capture and iTRAQ. J Proteome Res. 2009;8(4):1992–2003. doi:10.1021/pr800962q.

    Article  PubMed  CAS  Google Scholar 

  126. Csosz E, Boross P, Csutak A, Berta A, Toth F, Poliska S, et al. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012;75(7):2196–204. doi:10.1016/j.jprot.2012.01.019.

    Article  CAS  PubMed  Google Scholar 

  127. Kim HJ, Kim PK, Yoo HS, Kim CW. Comparison of tear proteins between healthy and early diabetic retinopathy patients. Clin Biochem. 2012;45(1–2):60–7. doi:10.1016/j.clinbiochem.2011.10.006.

    Article  CAS  PubMed  Google Scholar 

  128. Glasgow BJ, Marshall G, Gasymov OK, Abduragimov AR, Yusifov TN, Knobler CM. Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci. 1999;40(13):3100–7.

    CAS  PubMed  Google Scholar 

  129. Shamaei-Tousi A, Stephens JW, Bin R, Cooper JA, Steptoe A, Coates AR, et al. Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus. Eur Heart J. 2006;27(13):1565–70. doi:10.1093/eurheartj/ehl081.

    Article  CAS  PubMed  Google Scholar 

  130. Esposito G, Michelutti R, Verdone G, Viglino P, Hernandez H, Robinson CV, et al. Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci. 2000;9(5):831–45. doi:10.1110/ps.9.5.831.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Haritoglou C, Kernt M, Neubauer A, Gerss J, Oliveira CM, Kampik A, et al. Microaneurysm formation rate as a predictive marker for progression to clinically significant macular edema in nonproliferative diabetic retinopathy. Retina (Philadelphia, Pa). 2014;34(1):157–64. doi:10.1097/IAE.0b013e318295f6de.

    Article  CAS  Google Scholar 

  132. Ribeiro ML, Nunes SG, Cunha-Vaz JG. Microaneurysm turnover at the macula predicts risk of development of clinically significant macular edema in persons with mild nonproliferative diabetic retinopathy. Diabetes Care. 2013;36(5):1254–9. doi:10.2337/dc12-1491.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Klein R, Myers CE, Knudtson MD, Lee KE, Gangnon R, Wong TY, et al. Relationship of blood pressure and other factors to serial retinal arteriolar diameter measurements over time: the beaver dam eye study. Arch Ophthalmol. 2012;130(8):1019–27. doi:10.1001/archophthalmol.2012.560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care. 2008;31(9):1842–6. doi:10.2337/dc08-0189.

    Article  PubMed  PubMed Central  Google Scholar 

  135. •• Silva PS, Cavallerano JD, Tolls D, Omar A, Thakore K, Patel B, et al. Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. Diabetes Care. 2014;37(1):50–5. doi:10.2337/dc13-1292. This study suggests that ultrawide-field imaging is a more effective way to screen for DR and this could potentially change the screening practice guidelines in the future.

    Article  PubMed  Google Scholar 

  136. Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina (Philadelphia, Pa). 2012;32(4):785–91. doi:10.1097/IAE.0b013e3182278b64.

    Article  Google Scholar 

  137. Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–16. doi:10.1001/jamaophthalmol.2014.2350.

    Article  PubMed  Google Scholar 

  138. • Sun JK, Radwan SH, Soliman AZ, Lammer J, Lin MM, Prager SG, et al. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes. 2015;64(7):2560–70. doi:10.2337/db14-0782. This is a novel OCT imaging biomarker that is highly clinically relevant to predict the visual outcome in patients with diabetic macular edema.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Diabetic Retinopathy Clinical Research N, Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, et al. Observational study of subclinical diabetic macular edema. Eye (Lond). 2012;26(6):833–40. doi:10.1038/eye.2012.53.

    Article  Google Scholar 

  140. Bearse Jr MA, Adams AJ, Han Y, Schneck ME, Ng J, Bronson-Castain K, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25(5):425–48. doi:10.1016/j.preteyeres.2006.07.001.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Manolio T. Novel risk markers and clinical practice. N Engl J Med. 2003;349(17):1587–9. doi:10.1056/NEJMp038136.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Singapore National Eye Center, 11 Third Hospital Avenue, Singapore, 168751, Singapore

      Daniel Shu Wei Ting, Kara-Anne Tan, Val Phua, Gavin Siew Wei Tan, Chee Wai Wong & Tien Yin Wong

    2. Singapore Eye Research Institute, Singapore, Singapore

      Daniel Shu Wei Ting, Gavin Siew Wei Tan, Chee Wai Wong & Tien Yin Wong

    3. Duke-NUS Medical School, National University of Singapore, Singapore, Singapore

      Daniel Shu Wei Ting, Gavin Siew Wei Tan, Chee Wai Wong & Tien Yin Wong

    Authors
    1. Daniel Shu Wei Ting
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Kara-Anne Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Val Phua
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Gavin Siew Wei Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Chee Wai Wong
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Tien Yin Wong
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Tien Yin Wong.

    Ethics declarations

    Conflict of Interest

    Daniel S.W. Ting, Kara-Anne Tan, Val Phua, Gavin Tan, and Chee Wai Wong declare that they have no conflict of interest.

    Tien Yin Wong reports personal fees from Abbott, Novartis, Pfizer, Allergan, and Bayer.

    Human and Animal Rights and Informed Consent

    This article does not contain any studies with human or animal subjects performed by any of the authors.

    Additional information

    This article is part of the Topical Collection on Microvascular Complications—Retinopathy

    Chee Wai Wong and Tien Yin Wong contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Ting, D.S.W., Tan, KA., Phua, V. et al. Biomarkers of Diabetic Retinopathy. Curr Diab Rep 16, 125 (2016). https://doi.org/10.1007/s11892-016-0812-9

    Download citation

    • Published:

    • DOI: https://doi.org/10.1007/s11892-016-0812-9

    Keywords

    Search

    Navigation